A Phase 3 interventional study of Secukinumab and Secukinumab Placebo in Psoriatic Arthritis, Axial Spondyloarthritis and Enthesitis, sponsored by Novartis Pharmaceuticals. Completed at 55 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 14th largest by enrollment, is one of 5 that started in 2016, is one of 16 in phase 3, and was the 14th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 231 across the 26 interventional studies. Of the 22 that completed or were terminated, 17 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 26 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
31 studies in Arthritis, Psoriatic by Novartis: 3 open now, 3 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 31 studies in Arthritis, Psoriatic by Novartis, this one is the 15th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2016, is one of 14 in phase 3, and was the 13th registered.
Novartis’s Arthritis, Psoriatic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 31 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to demonstrate efficacy, including effects on inflammation by magnetic resonance imaging (MRI) assessments, of secukinumab on Achilles tendon enthesitis for up to 1 year with a primary focus at Week 24, in patients with active Psoriatic Arthritis and axial Spondyloarthritis despite current or previous non-steroidal anti-inflammatory drugs (NSAID) and/or disease modifying anti-rheumatic drug (DMARD) and/or anti-TNFα therapy.
Primary endpoint was at week 24 but there was no interim Clinical Study Report. While Protocol states at chapter 9.7 that a week 24 analysis may be provided (not mandatory as per protocol), all data has been analyzed at week 52.
Some of the secondary endpoints include the whole study period up to week 52 (to address questions on switching placebo to active drug)
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Secukinumab 150 mg s.c. or Secukinumab 300 mg s.c., respective dose was assigned according to underlying condition, in case of PsA according to severity of concomitant Psoriasis or pre-exposure to anti-TNFα
Biological: Secukinumab
Secukinumab Placebo s.c.
Drug: Secukinumab Placebo
Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4
Also known as: AIN457A
Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks
Also known as: AIN457/Secukinumab Placebo
Number (%) of Patients With Resolution of Achilles Tendon Enthesitis
Number (%) of patients with resolution of Achilles tendon enthesitis (affected foot) as assessed by respective subcomponent of Leeds enthesitis index (LEI) at Week 24. The primary analysis was performed via a logistic regression model with the factors treatment, country, and stratification factor diagnosis (PsA or axSpA); patients with a missing assessment were considered as responders if they had already met the response criterion at the time of last assessment.
Time frame: Week 24
Mean Change of Heel Pain
Mean change of heel pain from baseline to Week 24 measured by Numeric Rating Scale (NRS) ranging from 0 to 10, with 0 representing no pain and 10 representing worst pain (e.g. "pain as bad as you can imagine" or "worst pain imaginable").
Time frame: Week 24
Number (%) of Patients With Improvement of Bone Marrow Edema
Number (%) of patients with an improvement of bone marrow edema from baseline to Week 24 as assessed by the respective subcomponent of the Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) in the affected foot.
Time frame: Week 24
Number (%) of Patients With Resolution of Enthesitis as Assessed by LEI
Number (%) of patients with resolution of enthesitis as assessed by the Leeds enthesitis index (LEI) at Week 24.
Time frame: Week 24
Mean Change of Physician's Global Assessment of Disease Activity
Mean change of physician's global assessment (PhGA) of disease activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.
Time frame: Week 24
Mean Change of Patient's Global Assessment of Disease Activity
Mean change of patient's global assessment (PGA) of disease activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.
Time frame: Week 24
Mean Change of Physician's Assessment of Heel Enthesopathy Activity
Mean change of physician's assessment of heel enthesopathy activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.
Time frame: Week 24
Mean Change of Patient's Assessment of Heel Enthesopathy Activity
Mean change of patient's assessment of heel enthesopathy activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.
Time frame: Week 24
Mean Change in Short Form-36 (SF-36) v2
Mean change in Short Form-36 (SF-36) v2 as an indicator of overall health status The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability
Time frame: Week 24
Percentage of Patients With Resolution of Achilles Tendon Enthesitis After Switching From Placebo to Secukinumab
Percentage of patients with resolution of Achilles tendon enthesitis (affected foot) after switching from placebo to secukinumab at Week 24
Time frame: Weeks 24 and 52
Mean Change of Heel Pain After Switching From Placebo to Secukinumab
Mean change of heel pain after switching from placebo to secukinumab from Week 24 to week 52 measured by Numeric Rating Scale (NRS) ranging from 0 to 10, with 0 representing no pain and 10 representing worst pain (e.g. "pain as bad as you can imagine" or "worst pain imaginable").
Time frame: Change from week 24 to week 52
304 patients were screened. Of these, 94 patients discontinued during screening phase, 6 patients were re-screened and 204 patients completed the screening phase and were randomized in the trial.
| Milestone | Secukinumab | Placebo |
|---|---|---|
| Started | 102 | 102 |
| Completed | 91 | 84 |
| Not completed | 11 | 18 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Lack of efficacy | 3 | 6 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Withdrawal of informed consent | 1 | 5 |
| Milestone | Secukinumab | Placebo |
|---|---|---|
| Started | 91 | 84 |
| Completed | 89 | 81 |
| Not completed | 2 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Withdrawal of informed consent | 0 | 2 |
Number (%) of patients with resolution of Achilles tendon enthesitis (affected foot) as assessed by respective subcomponent of Leeds enthesitis index (LEI) at Week 24. The primary analysis was performed via a logistic regression model with the factors treatment, country, and stratification factor diagnosis (PsA or axSpA); patients with a missing assessment were considered as responders if they had already met the response criterion at the time of last assessment.
| Participants | Secukinumab | Placebo |
|---|---|---|
| Number (%) of Patients With Resolution of Achilles Tendon Enthesitis | 43 | 32 |
Mean change of heel pain from baseline to Week 24 measured by Numeric Rating Scale (NRS) ranging from 0 to 10, with 0 representing no pain and 10 representing worst pain (e.g. "pain as bad as you can imagine" or "worst pain imaginable").
| Scores on a scale | Secukinumab | Placebo |
|---|---|---|
| Mean Change of Heel Pain | -2.8 ± 2.99 | -1.9 ± 2.69 |
Number (%) of patients with an improvement of bone marrow edema from baseline to Week 24 as assessed by the respective subcomponent of the Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) in the affected foot.
| Participants | Secukinumab | Placebo |
|---|---|---|
| Number (%) of Patients With Improvement of Bone Marrow Edema | 17 | 12 |
Number (%) of patients with resolution of enthesitis as assessed by the Leeds enthesitis index (LEI) at Week 24.
| Participants | Secukinumab | Placebo |
|---|---|---|
| Number (%) of Patients With Resolution of Enthesitis as Assessed by LEI | 31 | 21 |
Mean change of physician's global assessment (PhGA) of disease activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.
| mm | Secukinumab | Placebo |
|---|---|---|
| Mean Change of Physician's Global Assessment of Disease Activity | -34.88 ± 25.927 | -18.93 ± 26.257 |
Mean change of patient's global assessment (PGA) of disease activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.
| mm | Secukinumab | Placebo |
|---|---|---|
| Mean Change of Patient's Global Assessment of Disease Activity | -25.87 ± 31.108 | -16.61 ± 29.235 |
Mean change of physician's assessment of heel enthesopathy activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.
| mm | Secukinumab | Placebo |
|---|---|---|
| Mean Change of Physician's Assessment of Heel Enthesopathy Activity | -38.40 ± 24.244 | -25.19 ± 25.250 |
Mean change of patient's assessment of heel enthesopathy activity from baseline to Week 24 measured by Visual Analog Scale (VAS) ranging from 0 to 100, with 0 representing not severe and 100 representing very severe.
| mm | Secukinumab | Placebo |
|---|---|---|
| Mean Change of Patient's Assessment of Heel Enthesopathy Activity | -31.05 ± 29.135 | -20.77 ± 30.417 |
Mean change in Short Form-36 (SF-36) v2 as an indicator of overall health status The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability
| scores on a scale | Secukinumab | Placebo |
|---|---|---|
| Mean Change in Short Form-36 (SF-36) v2 | 8.29 ± 9.759 | 5.28 ± 7.285 |
Percentage of patients with resolution of Achilles tendon enthesitis (affected foot) after switching from placebo to secukinumab at Week 24
| Participants | Secukinumab | Placebo |
|---|---|---|
| Week 24 | 43 | 32 |
| Week 52 | 66 | 55 |
Mean change of heel pain after switching from placebo to secukinumab from Week 24 to week 52 measured by Numeric Rating Scale (NRS) ranging from 0 to 10, with 0 representing no pain and 10 representing worst pain (e.g. "pain as bad as you can imagine" or "worst pain imaginable").
| Scores on a scale | Secukinumab | Placebo |
|---|---|---|
| Mean Change of Heel Pain After Switching From Placebo to Secukinumab | -0.70 ± 2.291 | -1.43 ± 2.251 |
Collected over Adverse events were collected from first dose of study treatment until end of study treatment at week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab | 0/102 (0%) | 7/102 (6.9%) | 33/102 (32.4%) |
| Placebo-Secukinumab | 0/102 (0%) | 6/102 (5.9%) | 34/102 (33.3%) |
| Event | Secukinumab | Placebo-Secukinumab |
|---|---|---|
| Atrial fibrillationCardiac disorders | 1/102 | 1/102 |
| GoitreEndocrine disorders | 0/102 | 1/102 |
| Abdominal adhesionsGastrointestinal disorders | 0/102 | 1/102 |
| Inflammatory bowel diseaseGastrointestinal disorders | 1/102 | 1/102 |
| Large intestinal stenosisGastrointestinal disorders | 0/102 | 1/102 |
| CellulitisInfections and infestations | 1/102 | 0/102 |
| DiverticulitisInfections and infestations | 0/102 | 1/102 |
| Pyelonephritis acuteInfections and infestations | 0/102 | 1/102 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/102 | 1/102 |
| Stress fractureInjury, poisoning and procedural complications | 0/102 | 1/102 |
| Event | Secukinumab | Placebo-Secukinumab |
|---|---|---|
| NasopharyngitisInfections and infestations | 13/102 | 22/102 |
| HeadacheNervous system disorders | 6/102 | 10/102 |
| DiarrhoeaGastrointestinal disorders | 8/102 | 5/102 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/102 | 5/102 |
| Upper respiratory tract infectionInfections and infestations | 6/102 | 5/102 |
Randomized Set: The Randomized set was defined as all patients who were randomized. Unless otherwise specified, mis-randomized patients in the IRT were excluded from the randomized set.
| Age, Categorical(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 97 | 95 | 192 |
| >=65 years | 5 | 7 | 12 |
| Age, Continuous(Years) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Mean | 47.8 ± 11.33 | 47.7 ± 11.02 | 47.7 ± 11.18 |
| Sex/Gender, Customized(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Female | 58 | 55 | 113 |
| Male | 44 | 47 | 91 |
| Race/Ethnicity, Customized(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Caucasian | 99 | 99 | 198 |
| Black | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 |
| Other | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Aug 2016 to primary completion in Dec 2019, 39 months.
Results were first posted in Jan 2021, 1 year 1 month after primary completion. A results delay was requested in Mar 2020.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 39 months is above that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab